AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10072215 — intervention group
Group type: EXPERIMENTAL
Intervention: Invasive strategy
Number of subjects: 0
Study 10072215 — intervention group
Group type: COMPARATOR
Intervention: Conservative strategy
Number of subjects: 0
Study 10072215 — intervention group
Group type: EXPERIMENTAL
Intervention: Health-related quality of life assessment using the Seattle Angina Questionnaire and Health Utilities Index
Number of subjects: 0
Study 7793189 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol mixed with prilocaine
Number of subjects: 48
Study 7793189 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol and lidocaine
Number of subjects: 48
Study 7793189 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol with prilocaine+lidocaine (equal amounts)
Number of subjects: 48
Study 7793189 — intervention group
Group type: COMPARATOR
Intervention: Propofol and saline
Number of subjects: 48
Study 7793189 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketorolac (30 mg)
Number of subjects: 48
Study 7793189 — intervention group
Group type: COMPARATOR
Intervention: Saline (equal volume to ketorolac)
Number of subjects: 48
Study 1795055 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.12% chlorhexidine gluconate (CHX) solution
Number of subjects: 51
Study 1795055 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.025% amine‐stannous fluoride (AmF + SnF) solution
Number of subjects: 51
Study 1795055 — intervention group
Group type: COMPARATOR
Intervention: 0.05% sodium fluoride (F) solution
Number of subjects: 51
Study 7236870 — intervention group
Group type: COMPARATOR
Intervention: 160 mg oral dose of 'Inderal' tablet (conventional formulation)
Number of subjects: 12
Study 7236870 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained release formulation 'Inderal' LA
Number of subjects: 12
Study 7236870 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical trial sustained release formulation
Number of subjects: 12
Study 7236870 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained release formulations (both)
Number of subjects: 12
Study 30576441 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% O2
Number of subjects: 1955
Study 30576441 — intervention group
Group type: COMPARATOR
Intervention: 5% O2 (control)
Number of subjects: 1955
Study 28719827 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous VNS (tVNS) during extinction phase
Number of subjects: 42
Study 28719827 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation during extinction phase
Number of subjects: 42
Study 25943394 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (with supplemental insulin if required)
Number of subjects: 222
Study 25943394 — intervention group
Group type: COMPARATOR
Intervention: Insulin
Number of subjects: 222
Study 23052515 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined general-epidural anesthesia (group GE)
Number of subjects: 45
Study 23052515 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia (group G)
Number of subjects: 45
Study 21741089 — intervention group
Group type: EXPERIMENTAL
Intervention: Biphasic insulin aspart 70/30 (BIAsp 30)
Number of subjects: 716
Study 19095875 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg tramadol
Number of subjects: 102
Study 19095875 — intervention group
Group type: COMPARATOR
Intervention: 4 mL saline (control group)
Number of subjects: 102
Study 19095875 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg tramadol and 2 mL saline (TL group)
Number of subjects: 102
Study 15844317 — intervention group
Group type: EXPERIMENTAL
Intervention: Lornoxicam
Number of subjects: 39
Study 15844317 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl
Number of subjects: 39
Study 11807305 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-1 genotyping
Number of subjects: 326
Study 11807305 — intervention group
Group type: EXPERIMENTAL
Intervention: Expert advice
Number of subjects: 326
Study 11807305 — intervention group
Group type: COMPARATOR
Intervention: No genotyping
Number of subjects: 326
Study 10072411 — intervention group
Group type: EXPERIMENTAL
Intervention: Liposomal amphotericin B
Number of subjects: 687
Study 10072411 — intervention group
Group type: COMPARATOR
Intervention: Conventional amphotericin B
Number of subjects: 687
Study 8749628 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentagastrin
Number of subjects: 19
Study 8749628 — intervention group
Group type: EXPERIMENTAL
Intervention: Glutamic acid
Number of subjects: 19
Study 8749628 — intervention group
Group type: COMPARATOR
Intervention: Baseline period
Number of subjects: 19
Study 2024815 — intervention group
Group type: EXPERIMENTAL
Intervention: Influenza A/Bethesda/1/85 (H3N2)
Number of subjects: 11
Study 2024815 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 7029292 — intervention group
Group type: COMPARATOR
Intervention: Adjuvant chemotherapy with Adriamycin and cyclophosphamide (Cytoxan) in soft tissue sarcomas
Number of subjects: 105
Study 7029292 — intervention group
Group type: COMPARATOR
Intervention: High-dose methotrexate following surgery in osteogenic sarcoma
Number of subjects: 105
Study 7029292 — intervention group
Group type: COMPARATOR
Intervention: Frequent screening for pulmonary metastases and surgical resection of these metastases in osteogenic sarcoma
Number of subjects: 105
Study 31464343 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention (diet and exercise)
Number of subjects: 360
Study 31144258 — intervention group
Group type: EXPERIMENTAL
Intervention: McGrath MAC videolaryngoscope (MVL)
Number of subjects: 120
Study 31144258 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentax Airway Scope (PVL)
Number of subjects: 120
Study 31144258 — intervention group
Group type: COMPARATOR
Intervention: Macintosh direct laryngoscope (DL)
Number of subjects: 120
Study 27596027 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based physiotherapy (8 weeks, twice per week)
Number of subjects: 24
Study 27596027 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 24
Study 25245489 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentosan polysulfate sodium 100 mg once daily
Number of subjects: 368
Study 25245489 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentosan polysulfate sodium 100 mg three times daily
Number of subjects: 368
Study 25245489 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 368
Study 23588794 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous sumatriptan injection (6 mg)
Number of subjects: 18
Study 21301814 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg D-cycloserine (DCS)
Number of subjects: 48
Study 21301814 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 21301814 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg D-cycloserine (DCS) with partial smoking
Number of subjects: 48
Study 21301814 — intervention group
Group type: COMPARATOR
Intervention: Placebo with partial smoking
Number of subjects: 48
Study 18973950 — intervention group
Group type: EXPERIMENTAL
Intervention: Photodynamic therapy (PDT) with intravenous verteporfin at 6 mg/m² body surface, laser beam applied at radiant exposure 50 J/cm² for 83 seconds, 1 to 4 treatments at 12-week intervals over 1 year.
Number of subjects: 31
Study 18973950 — intervention group
Group type: EXPERIMENTAL
Intervention: Photodynamic therapy (PDT)
Number of subjects: 31
Study 17479927 — intervention group
Group type: EXPERIMENTAL
Intervention: Elaborative encoding
Number of subjects: 0
Study 17479927 — intervention group
Group type: COMPARATOR
Intervention: Rote rehearsal
Number of subjects: 0
Study 17479927 — intervention group
Group type: EXPERIMENTAL
Intervention: Verbalisation during encoding
Number of subjects: 0
Study 15198886 — intervention group
Group type: EXPERIMENTAL
Intervention: Stroke Unit (SU)
Number of subjects: 392
Study 15198886 — intervention group
Group type: COMPARATOR
Intervention: General Ward (GW)
Number of subjects: 392
Study 11770871 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin treatment for > or = 6 months before hospital admission
Number of subjects: 1000
Study 9674006 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac 0.1%
Number of subjects: 26
Study 9674006 — intervention group
Group type: COMPARATOR
Intervention: Prednisolone acetate 1%
Number of subjects: 26
Study 9674006 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 26
Study 8077738 — intervention group
Group type: COMPARATOR
Intervention: 1 day of parenteral clindamycin (standard prophylaxis)
Number of subjects: 0
Study 8077738 — intervention group
Group type: COMPARATOR
Intervention: 1 day of topical clindamycin
Number of subjects: 0
Study 8077738 — intervention group
Group type: COMPARATOR
Intervention: 5 days of topical clindamycin
Number of subjects: 0
Study 8077738 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 day of topical amoxicillin plus clavulanate/ticarcillin plus clavulanate
Number of subjects: 0
Study 2642629 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral milrinone
Number of subjects: 750
Study 2642629 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 750
Study 1103330 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrazepam
Number of subjects: 0
Study 1103330 — intervention group
Group type: EXPERIMENTAL
Intervention: Triazolam
Number of subjects: 0
Study 1103330 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurazepam
Number of subjects: 0
Study 1103330 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31228055 — intervention group
Group type: EXPERIMENTAL
Intervention: ASM-Enhanced Collaborative Care (CSM)
Number of subjects: 294
Study 31228055 — intervention group
Group type: COMPARATOR
Intervention: Automated Self-management (ASM)
Number of subjects: 294
Study 28719305 — intervention group
Group type: EXPERIMENTAL
Intervention: Price reduction ($0.11‐$0.56 per chlorine bottle)
Number of subjects: 1798
Study 28719305 — intervention group
Group type: EXPERIMENTAL
Intervention: Price reduction
Number of subjects: 1798
Study 28719305 — intervention group
Group type: EXPERIMENTAL
Intervention: Monthly visits from sales agents
Number of subjects: 1798
Study 28719305 — intervention group
Group type: EXPERIMENTAL
Intervention: Price discounts
Number of subjects: 1798
Study 28719305 — intervention group
Group type: EXPERIMENTAL
Intervention: Lowest price and conducting visits
Number of subjects: 1798
Study 28719305 — intervention group
Group type: EXPERIMENTAL
Intervention: Slightly raising the retail price and not conducting visits
Number of subjects: 1798
Study 26272768 — intervention group
Group type: EXPERIMENTAL
Intervention: Rolapitant (180 mg dose)
Number of subjects: 1369
Study 26272768 — intervention group
Group type: COMPARATOR
Intervention: Active control (placebo)
Number of subjects: 1369
Study 26272768 — intervention group
Group type: EXPERIMENTAL
Intervention: Rolapitant
Number of subjects: 1369
Study 26272768 — intervention group
Group type: COMPARATOR
Intervention: Active control
Number of subjects: 1369
Study 22719016 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg of chlorpheniramine
Number of subjects: 16
Study 22719016 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 16
Study 22719016 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg of caffeine
Number of subjects: 16
Study 22719016 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg of chlorpheniramine-200 mg of caffeine
Number of subjects: 16
Study 22719016 — intervention group
Group type: EXPERIMENTAL
Intervention: chlorpheniramine-placebo
Number of subjects: 16
Study 21754985 — intervention group
Group type: EXPERIMENTAL
Intervention: Valproic acid (VPA) and L-carnitine for 12 months
Number of subjects: 33
Study 18641770 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% manitol (M Group, n=40)
Number of subjects: 80
Study 18641770 — intervention group
Group type: COMPARATOR
Intervention: Polyethyleneglycol (PEG Group, n=40)
Number of subjects: 80
Study 18641770 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 80
Study 16307157 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training
Number of subjects: 28
Study 16307157 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-exercising)
Number of subjects: 28
Study 16307157 — intervention group
Group type: COMPARATOR
Intervention: Comparison of control and resistance training groups
Number of subjects: 28
Study 11782819 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg valdecoxib twice daily
Number of subjects: 0
Study 11782819 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg valdecoxib twice daily
Number of subjects: 0
Study 11782819 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 9653559 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic appendectomy
Number of subjects: 54
Study 9653559 — intervention group
Group type: COMPARATOR
Intervention: Conventional appendectomy
Number of subjects: 54
Study 8590611 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenytoin (PHT) 100 mg, PO, tid
Number of subjects: 24
Study 8590611 — intervention group
Group type: COMPARATOR
Intervention: Standard detoxification therapy
Number of subjects: 24
Study 8590611 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenytoin (PHT) 50-100 mg, bid-tid after acute withdrawal
Number of subjects: 24
Study 2492178 — intervention group
Group type: COMPARATOR
Intervention: Bilateral myringotomy and no additional treatment (group 1)
Number of subjects: 578
Study 2492178 — intervention group
Group type: EXPERIMENTAL
Intervention: Tympanostomy tubes (group 2)
Number of subjects: 578
Study 2492178 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenoidectomy and myringotomy (group 3)
Number of subjects: 578
Study 2492178 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenoidectomy and tympanostomy tubes (group 4)
Number of subjects: 578
Study 1091151 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenine arabinoside 20 mg/kg/day intravenous infusions for seven days
Number of subjects: 0
Study 1091151 — intervention group
Group type: COMPARATOR
Intervention: Adenine arabinoside
Number of subjects: 0
Study 30895579 — intervention group
Group type: EXPERIMENTAL
Intervention: Video laryngoscopy
Number of subjects: 27
Study 30895579 — intervention group
Group type: COMPARATOR
Intervention: Direct laryngoscopy
Number of subjects: 27
Study 29336823 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive control material for CT and NG testing using GeneXpert (Xpert) assay.
Number of subjects: 89
Study 27281720 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraneural injection (group INTRA)
Number of subjects: 88
Study 27281720 — intervention group
Group type: COMPARATOR
Intervention: Subparaneural injection (group SUBPARA)
Number of subjects: 88
Study 27281720 — intervention group
Group type: EXPERIMENTAL
Intervention: Both techniques
Number of subjects: 88
Study 24804714 — intervention group
Group type: EXPERIMENTAL
Intervention: Hearing conservation intervention for rural students
Number of subjects: 392
Study 22809586 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypofractionated radiotherapy (5 fractions of 5.7 or 6.0 Gy over 5 weeks)
Number of subjects: 915
Study 22809586 — intervention group
Group type: COMPARATOR
Intervention: Standard fractionation (control group)
Number of subjects: 915
Study 20546592 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical coordination training
Number of subjects: 758
Study 20546592 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural theory-based training
Number of subjects: 758
Study 20546592 — intervention group
Group type: COMPARATOR
Intervention: Reference group
Number of subjects: 758
Study 18697216 — intervention group
Group type: EXPERIMENTAL
Intervention: LAM (arm 1)
Number of subjects: 36
Study 18697216 — intervention group
Group type: EXPERIMENTAL
Intervention: TDF (arm 2)
Number of subjects: 36
Study 18697216 — intervention group
Group type: EXPERIMENTAL
Intervention: LAM/TDF (arm 3)
Number of subjects: 36
Study 15850631 — intervention group
Group type: EXPERIMENTAL
Intervention: Amodiaquine
Number of subjects: 1811
Study 15850631 — intervention group
Group type: EXPERIMENTAL
Intervention: Amodiaquine + sulfadoxine‐pyrimethamine
Number of subjects: 1811
Study 15850631 — intervention group
Group type: EXPERIMENTAL
Intervention: Amodiaquine + artesunate
Number of subjects: 1811
Study 15850631 — intervention group
Group type: EXPERIMENTAL
Intervention: Artemether‐lumefantrine
Number of subjects: 1811
Study 12530594 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to PCBs and PCDFs
Number of subjects: 60
Study 12530594 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up after 9 months
Number of subjects: 60
Study 12530594 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum PCBs
Number of subjects: 60
Study 12530594 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up serum PCB levels
Number of subjects: 60
Study 12530594 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum toxic equivalency (TEQ) for total PCDDs and PCDFs
Number of subjects: 60
Study 12530594 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term health effects
Number of subjects: 60
Study 9601827 — intervention group
Group type: EXPERIMENTAL
Intervention: Haemaccel
Number of subjects: 20
Study 9601827 — intervention group
Group type: COMPARATOR
Intervention: Ringer's lactate
Number of subjects: 20
Study 8026195 — intervention group
Group type: EXPERIMENTAL
Intervention: PGE1 (30 ng/kg/min)
Number of subjects: 30
Study 8026195 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 2542427 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous insulin infusion (CSII) therapy
Number of subjects: 11
Study 2542427 — intervention group
Group type: COMPARATOR
Intervention: Conventional insulin therapy (CIT)
Number of subjects: 11
Study 31139982 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic appendectomy (LA)
Number of subjects: 126
Study 31139982 — intervention group
Group type: COMPARATOR
Intervention: Open appendectomy (OA)
Number of subjects: 126
Study 28520672 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 62
Study 28520672 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study 25359302 — intervention group
Group type: EXPERIMENTAL
Intervention: HHV-8 seropositivity
Number of subjects: 630
Study 25359302 — intervention group
Group type: COMPARATOR
Intervention: Control group (no HHV-8 seropositivity)
Number of subjects: 630
Study 23725996 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast walkers (6MWTD >128.5 meters)
Number of subjects: 484
Study 23725996 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow walkers (6MWTD below median 128.5 meters)
Number of subjects: 484
Study 23725996 — intervention group
Group type: EXPERIMENTAL
Intervention: Unable to walk
Number of subjects: 484
Study 23725996 — intervention group
Group type: COMPARATOR
Intervention: Slow walkers
Number of subjects: 484
Study 23725996 — intervention group
Group type: COMPARATOR
Intervention: Fast walkers
Number of subjects: 484
Study 21839983 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional physiotherapy + Aerobic exercise (intervention group)
Number of subjects: 46
Study 21839983 — intervention group
Group type: COMPARATOR
Intervention: Conventional physiotherapy (control group)
Number of subjects: 46
Study 20088414 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture under continuous traction in prone position (Group A)
Number of subjects: 119
Study 20088414 — intervention group
Group type: COMPARATOR
Intervention: Electroacupuncture after supine position traction (Group B)
Number of subjects: 119
Study 20088414 — intervention group
Group type: COMPARATOR
Intervention: Electroacupuncture only (Group C)
Number of subjects: 119
Study 17224222 — intervention group
Group type: EXPERIMENTAL
Intervention: PNB classification by nine independent observers
Number of subjects: 100
Study 15485437 — intervention group
Group type: EXPERIMENTAL
Intervention: Digitalis and beta-blocker during isoproterenol infusion
Number of subjects: 40
Study 15485437 — intervention group
Group type: COMPARATOR
Intervention: Control group (no additional treatment)
Number of subjects: 40
Study 15485437 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow pathway ablation (RFA)
Number of subjects: 40
Study 15485437 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoproterenol infusion
Number of subjects: 40
Study 11507585 — intervention group
Group type: EXPERIMENTAL
Intervention: Patching
Number of subjects: 64
Study 11507585 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine
Number of subjects: 64
Study 11507585 — intervention group
Group type: COMPARATOR
Intervention: Patching and Atropine
Number of subjects: 64
Study 9753263 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisapride 20 mg twice daily for six months
Number of subjects: 34
Study 9753263 — intervention group
Group type: COMPARATOR
Intervention: Partial posterior fundoplication without cisapride
Number of subjects: 34
Study 7826831 — intervention group
Group type: EXPERIMENTAL
Intervention: 97 mg amoxycillin sodium (0.25 mmol)
Number of subjects: 6
Study 7826831 — intervention group
Group type: EXPERIMENTAL
Intervention: 3103 mg amoxycillin sodium (8 mmol)
Number of subjects: 6
Study 30197311 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil injection (2 mL) around the anastomosis site before and after surgery (2, 4, 6, 8, and 10 weeks after surgery)
Number of subjects: 32
Study 30197311 — intervention group
Group type: COMPARATOR
Intervention: Control group (anastomosis surgery only)
Number of subjects: 32
Study 27185164 — intervention group
Group type: EXPERIMENTAL
Intervention: FP/FORM (100/10 µg b.i.d.)
Number of subjects: 211
Study 27185164 — intervention group
Group type: COMPARATOR
Intervention: FP/SAL (100/50 µg b.i.d.)
Number of subjects: 211
Study 27185164 — intervention group
Group type: EXPERIMENTAL
Intervention: FP/FORM
Number of subjects: 211
Study 27185164 — intervention group
Group type: COMPARATOR
Intervention: FP/FORM and FP/SAL
Number of subjects: 211
Study 24190232 — intervention group
Group type: EXPERIMENTAL
Intervention: MSUS-guided injection of 40 mg of methylprednisolone acetate (Group 2, n = 59)
Number of subjects: 100
Study 24190232 — intervention group
Group type: COMPARATOR
Intervention: Palpation-guided injection (Group 1, n = 66)
Number of subjects: 100
Study 22441150 — intervention group
Group type: EXPERIMENTAL
Intervention: Holmium laser lithotripsy (LL) using a 550‐μm fiber
Number of subjects: 80
Study 22441150 — intervention group
Group type: COMPARATOR
Intervention: Pneumatic lithotripsy (PL) using the Swiss Lithoclast
Number of subjects: 80
Study 20453461 — intervention group
Group type: EXPERIMENTAL
Intervention: HYBT (Hybrid training method)
Number of subjects: 20
Study 20453461 — intervention group
Group type: COMPARATOR
Intervention: WMT (Weight machine training)
Number of subjects: 20